While all PPIs have been associated with adverse metabolic effects—such as reduced serum magnesium and insulin-like growth factor-1 (IGF-1) levels—which may contribute to insulin resistance, impaired renal urate excretion, and systemic inflammation, lansoprazole appears to differ mechanistically. The gene discussed is IGF1; the disease is Insulin resistance.